This article is more than 5 years old. Information may no longer be current.

CIBA, Bausch & Lomb settle silicone hydrogel lawsuits

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y., and ATLANTA – Bausch & Lomb and CIBA Vision Corp., the eye care unit of Novartis AG, announced Friday in a joint press release that they have agreed to cross-license rights to their silicone hydrogel contact lens technologies. Bausch & Lomb will pay CIBA Vision a royalty on net U.S. sales of its PureVision brand contact lenses until 2014 and on net sales outside the U.S. until 2016. Bausch & Lomb may resume sale and manufacture of PureVision brand contact lenses in the United States on April 27, 2005, upon expiration of the Harvey patent, which was the subject of a 2002 ruling in the Federal District Court in Delaware.

PureVision brand lenses will continue to be available outside the United States, according to the press release. CIBA Vision’s Focus Night & Day lenses continue to be available worldwide.

This settlement, which is effective immediately, resolves patent lawsuits in the United States in Federal District Courts in Georgia, Delaware and New York, as well as other lawsuits and patent proceedings in Germany, Ireland, the European Patent Office and Australia.